Compare Amylx Pharmaceuticals Inc (AMLX) vs Unity Software Inc (U) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Unity Software Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Unity Software Inc trades at $31.15 (market cap $13.48B). The key difference: Unity Software Inc is far larger — about 6.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Unity Software Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | U | |
|---|---|---|
Market Cap | $1.98B | $13.48B |
Sector | Health | Technology |
52-Week High | $18.70 | $49.47 |
52-Week Low | $7.64 | $17.13 |
Enterprise Value | $1.70B | $13.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Unity Software (U) trades at $30.89, up 0.52% today, with a bullish technical signal and strong analyst consensus. The stock shows improving revenue trends ($1.85B in 2025) and narrowing losses, though profitability remains negative. Recent news highlights momentum in AI advertising and cost restructuring, with Q2 2026 earnings expected on August 5, 2026.
Outlook: Growth potential exists through AI integration and margin expansion, but persistent net losses and high valuation multiples pose risks. Analyst price target of $36.50 suggests 18% upside, supported by bullish sentiment, yet investors must weigh execution risks against transformative opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
